Tesetaxel for Previously Treated Patients With Bladder Cancer

Inclusion Criteria

• •At least 18 years of age
• •Histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis
• •Measurable disease (revised RECIST; Version 1.1)
• •Karnofsky performance status ≥ 60%
• •Previously treated with not more than 1 doublet or triplet regimen and that regimen contained gemcitabine and a platinum agent
• •Adequate bone marrow, hepatic, and renal function, as specified in the protocol
• •At least 4 weeks and recovery from effects of prior surgery, prior radiotherapy, or other therapy with an approved or investigational agent
• •Ability to swallow an oral solid-dosage form of medication